A team of researchers has developed microparticles capable of carrying three different molecules on three different docks, or "patches." They could eventually provide a one-two-three punch against cancer, the researchers say.
Seno Medical Instruments raised $34.6 million of a planned $39 million Series C equity funding round. The company will use the funds for a pivotal U.S. study of its breast cancer diagnostic device, and to obtain CE mark approval for the device in Europe, it said in a statement.
The antibiotics developer Achaogen has set its terms for a planned IPO, saying it will sell 5 million shares at $12 to $14 a share.
Neuromodulation is one of those medical device industry segments that are poised for some major growth in the coming years, based on projections compiled by the research outfit EvaluateMedTech.
Quanttus pulled in a $19 million Series A funding round and plans to use the money to advance work on wearable clinical monitoring technology with development mojo from Apple and the Massachusetts Institute of Technology, among others.
Houston biotech DNAtrix has secured a $10.8 million grant to fund clinical development of its oncolytic virus to treat brain cancer, contending with a trove of drugmakers in the promising space.
Pfizer is one step closer to another $1 billion-plus in sales for its Prevnar 13 franchise. Data from a huge new study showed that Prevnar worked at preventing pneumonia in patients 65 or older, which puts the vaccine in line for stepped-up use.
A busy Servier wants to explore Celladon's technology to see if there are some small molecule applications to diabetes and other metabolic conditions that warrant clinical development.
Scientists use 3-D printing to construct everything from hearing aids to dental crowns. But Organovo Holdings wants to take 3-D printing one step further and create living tissue that could be used in testing and organ transplants, Bloomberg reported.
Charles River Laboratories is kicking off an all-encompassing service that will allow its biotech and pharma clients to hand over their quality-control testing for biologics en masse, a method the preclinical CRO says can save time and money.